These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38778126)

  • 1. CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children.
    Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl ML; Aklillu E
    Sci Rep; 2024 May; 14(1):11730. PubMed ID: 38778126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda.
    Barry A; Kabatende J; Telele NF; Mnkugwe RH; Mugisha M; Ntirenganya L; Bienvenu E; Aklillu E
    Sci Rep; 2023 Jan; 13(1):1446. PubMed ID: 36702944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania.
    Mnkugwe RH; Minzi O; Kinung'hi S; Kamuhabwa A; Aklillu E
    Front Pharmacol; 2021; 12():712084. PubMed ID: 34531744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.
    Bajiro M; Dana D; Ayana M; Emana D; Mekonnen Z; Zawdie B; Garbi A; Kure A; Zeynudin A
    Parasit Vectors; 2016 Oct; 9(1):560. PubMed ID: 27772528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
    Bustinduy AL; Waterhouse D; de Sousa-Figueiredo JC; Roberts SA; Atuhaire A; Van Dam GJ; Corstjens PL; Scott JT; Stanton MC; Kabatereine NB; Ward S; Hope WW; Stothard JR
    mBio; 2016 Aug; 7(4):. PubMed ID: 27507822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019.
    Chisha Y; Zerdo Z; Asnakew M; Churko C; Yihune M; Teshome A; Nigussu N; Seife F; Getachew B; Sileshi M
    BMC Infect Dis; 2020 Nov; 20(1):872. PubMed ID: 33225918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel.
    Nleya L; Thelingwani R; Li XQ; Cavallin E; Isin E; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1077-1087. PubMed ID: 31089768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients.
    Meister I; Kovac J; Duthaler U; Odermatt P; Huwyler J; Vanobberghen F; Sayasone S; Keiser J
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004700. PubMed ID: 27152952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia.
    Erko B; Degarege A; Tadesse K; Mathiwos A; Legesse M
    Asian Pac J Trop Biomed; 2012 Mar; 2(3):235-9. PubMed ID: 23569905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
    Abla N; Keiser J; Vargas M; Reimers N; Haas H; Spangenberg T
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005942. PubMed ID: 28934207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST).
    Hoekstra PT; Casacuberta-Partal M; van Lieshout L; Corstjens PLAM; Tsonaka R; Assaré RK; Silué KD; Meité A; N'Goran EK; N'Gbesso YK; Amoah AS; Roestenberg M; Knopp S; Utzinger J; Coulibaly JT; van Dam GJ
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008189. PubMed ID: 32196506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.
    Abudho BO; Ndombi EM; Guya B; Carter JM; Riner DK; Kittur N; Karanja DMS; Secor WE; Colley DG
    Am J Trop Med Hyg; 2018 May; 98(5):1397-1402. PubMed ID: 29532768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel.
    Kapungu NN; Li X; Nhachi C; Masimirembwa C; Thelingwani RS
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00618. PubMed ID: 32700798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities.
    Botros SS; El-Din SH; El-Lakkany NM; Sabra AN; Ebeid FA
    J Parasitol; 2006 Dec; 92(6):1344-9. PubMed ID: 17304818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and bioavailability of different praziquantel brands.
    Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
    Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models.
    Zdesenko G; Mutapi F
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008649. PubMed ID: 32976496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal single sampling time-point for monitoring of praziquantel exposure in children.
    Mnkugwe RH; Ngaimisi Kitabi E; Kinung'hi S; Kamuhabwa AAR; Minzi OM; Aklillu E
    Sci Rep; 2021 Sep; 11(1):17955. PubMed ID: 34504222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections.
    Coeli R; Baba EH; Araujo N; Coelho PM; Oliveira G
    PLoS Negl Trop Dis; 2013; 7(12):e2596. PubMed ID: 24367712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
    Garba A; Lamine MS; Barkiré N; Djibo A; Sofo B; Gouvras AN; Labbo R; Sebangou H; Webster JP; Fenwick A; Utzinger J
    Acta Trop; 2013 Nov; 128(2):334-44. PubMed ID: 22940014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and genotypic monitoring of Schistosoma mansoni in Tanzanian schoolchildren five years into a preventative chemotherapy national control programme.
    Gower CM; Gehre F; Marques SR; Lamberton PHL; Lwambo NJ; Webster JP
    Parasit Vectors; 2017 Dec; 10(1):593. PubMed ID: 29197426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.